Palbociclib - from Bench to Bedside and Beyond

Publisher： Karger

E-ISSN： 1661-3805|11|3|177-181

ISSN： 1661-3791

Source： Breast Care, Vol.11, Iss.3, 2016-06, pp. : 177-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunological Mechanisms in Breast Cancer - from Bench to Bedside

By  

Breast Care, Vol. 11, Iss. 2, 2016-04 ,pp. : 93-94

Karger

Access to resources Recommend Favorite

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

By  

Breast Care, Vol. 11, Iss. 3, 2016-06 ,pp. : 174-176

Karger

Access to resources Recommend Favorite

Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

By  

Breast Care, Vol. 11, Iss. 2, 2016-02 ,pp. : 133-138

Karger

Access to resources Recommend Favorite

Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 168-171

Karger

Access to resources Recommend Favorite

News from ASCO 2017

By  

Breast Care, Vol. 12, Iss. 4, 2017-08 ,pp. : 266-268

Karger

Access to resources Recommend Favorite